Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Laurence B. McCullough, PhD, Frank A. Chervenak, MD, and John H. Coverdale, MD, MEd
The best interests of a pregnant psychotic patient can be served by determining her decision making capacity and using surrogate decision making if needed.
AMA J Ethics. 2016; 18(3):209-214. doi:
10.1001/journalofethics.2016.18.3.ecas2-1603.
As high-tech care decisions led to value clashes in hospital corridors, ethics committees developed to respond to diverse viewpoints, families’ concerns, and clinicians’ moral distress. They now exist in almost all US health care organizations.
AMA J Ethics. 2016; 18(5):546-553. doi:
10.1001/journalofethics.2016.18.5.mhst1-1605.
Patients can now easily view their health records, so clinicians must consider a reader’s interpretation of how they convey sensitive personal health information. What might this mean for ethics consultants?
AMA J Ethics. 2020; 22(9):E784-791. doi:
10.1001/amajethics.2020.784.